Dong L, Wang JA, Jiang CY Validation of the use of foreign gas rebreathing method for non-invasive determination of cardiac output in heart disease patients. J Zhejiang Univ Sci B. 2005 Dec;6(12):1157-62.
Fontana P, Boutellier U, Toigo M Reliability of measurements with Innocor during exercise. Int J Sports Med. 2009 Oct;30(10):747-53. doi: 10.1055/s-0029-1225340. Epub 2009 Jul 29.
Sanders SP, Yeager S, Williams RG Measurement of systemic and pulmonary blood flow and QP/QS ratio using Doppler and two-dimensional echocardiography. Am J Cardiol. 1983 Mar 15;51(6):952-6.
Taylor K, La Rotta G, McCrindle BW, Manlhiot C, Redington A, Holtby H A comparison of cardiac output by thoracic impedance and direct fick in children with congenital heart disease undergoing diagnostic cardiac catheterization. J Cardiothorac Vasc Anesth. 2011 Oct;25(5):776-9. doi: 10.1053/j.jvca.2011.05.002.
Warburton DE, Haykowsky MJ, Quinney HA, Humen DP, Teo KK Reliability and validity of measures of cardiac output during incremental to maximal aerobic exercise. Part II: Novel techniques and new advances. Sports Med. 1999 Apr;27(4):241-60. Review.
Wiegand G, Binder W, Ulmer H, Kaulitz R, Riethmueller J, Hofbeck M Noninvasive cardiac output measurement at rest and during exercise in pediatric patients after interventional or surgical atrial septal defect closure. Pediatr Cardiol. 2012 Oct;33(7):1109-14. doi: 10.1007/s00246-012-0239-2. Epub 2012 Feb 22.
Wiegand G, Kerst G, Baden W, Hofbeck M Noninvasive cardiac output determination for children by the inert gas-rebreathing method. Pediatr Cardiol. 2010 Nov;31(8):1214-8. doi: 10.1007/s00246-010-9806-6. Epub 2010 Oct 13.
Shunt Quantification in Atrial Septal Defect Using Inert Gas Rebreathing and Thoracic Bioimpedance: Comparison With the Gold Standard Method
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
